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Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis
Ton Lisman, Philip G. de Groot, Joost C.M. Meijers, and Frits R. Rosendaal
The role of the fibrinolytic system in the
development of deep vein thrombosis
(DVT) is unclear. We determined the
plasma fibrinolytic potential of patients
enrolled in the Leiden Thrombophilia
Study (LETS), a population-based case-
control study on risk factors for DVT.
Plasma fibrinolytic potential was deter-
mined in 421 patients and 469 control
subjects by means of a tissue factor–
induced and tissue-type plasminogen ac-
tivator (tPA)–induced clot lysis assay. Us-
ing clot lysis times above the 70th, 80th,
90th, 95th, and 99th percentiles of the
values found in control subjects as cut-
off levels, we found a dose-dependent
increase in risk for DVT in patients with
hypofibrinolysis (odds ratios of 1.4, 1.6,
1.9, 2.1, and 2.2, respectively). This indi-
cates a 2-fold increased risk of DVT in
subjects with clot lysis times above the
90th percentile. The risk increase was not
affected by age or sex (adjusted odds
ratio for 90th percentile, 2.0), and after
correction for all possible confounders
(age, sex, and levels of procoagulant pro-
teins shown to associate with clot lysis
times in the control population), the risk
estimate was marginally reduced (odds
ratio, 1.6 for 90th percentile). Taken to-
gether, these results indicate that plasma
hypofibrinolysis constitutes a risk factor
for venous thrombosis, with a doubling of
the risk at clot lysis times that are present
in 10% of the population. (Blood. 2005;
105:1102-1105)
© 2005 by The American Society of Hematology
Introduction
Evidence for a role of fibrinolysis, the dissolution of a fibrin clot, in
the etiology of venous thrombosis is scarce. Genetic evidence has
been limited to reports on patients with hereditary plasminogen
deficiency,1 although the relationship between heterozygous plas-
minogen deficiency and thrombosis has been questioned (for a
review, see Brandt2). Moreover, homozygous plasminogen defi-
ciency is not associated with deep vein thrombosis (DVT), but
rather presents as ligneous conjunctivitis caused by vascular
deposition of fibrin within the eye.3
Elevated levels of plasminogen activator inhibitor type 1
(PAI-1), and the PAI-1 4G/5G polymorphism have been suggested
as a risk factor for venous thrombosis, but data are highly
conflicting and unconvincing (for a review, see Francis4). Baseline
plasma levels of tissue-type plasminogen activator (tPA) did not
predict a first episode of venous thrombosis5 nor did they predict
the risk of recurrence.6 Elevated plasma levels of thrombin
activatable fibrinolysis inhibitor (TAFI), however, were a mild risk
factor for the development of venous thrombosis.7 Next to levels of
proteins involved in fibrinolysis, levels of markers of fibrinolytic
activity were studied in relation to the development of venous
thrombosis. Levels of tPA/PAI-1 complex and plasmin-antiplasmin
(PAP) complex were not associated with an increased risk for
venous thrombosis.8
Studies on a relationship between fibrinolysis and venous
thrombosis have focused on plasma levels of proteins or protease-
inhibitor complexes. Global tests of fibrinolytic activity such as the
euglobulin clot lysis time (ECLT) and the dilute whole-blood clot
lysis time (DWBCLT) have been used to study the association of
thrombosis and hypofibrinolysis, but these studies gave inconclu-
sive results (summarized by Prins and Hirsh9). Moreover, the
outcome of these tests do not reflect a true global fibrinolytic
potential, because these tests are either performed with plasma
fractions (ECLT) or in the presence of citrate (DWBCLT), which
excludes the interplay between coagulation and fibrinolysis through
TAFI and factor XIII.
We have developed a plasma-based, tissue factor-induced clot
lysis assay, in which a fibrin clot is lysed by exogenously added
tPA. Although this assay was initially developed to study TAFI-
related processes, we have shown that the clot lysis time (CLT) in
this assay is also influenced by levels of other proteins involved in
fibrinolysis and thrombin generation (which is required for TAFI
activation), including plasminogen, 2-antiplasmin, PAI-1, and
antithrombin.10 The outcome of this assay therefore reflects an
overall plasma fibrinolytic potential. This test has been used to
study fibrinolysis in a number of pathologies. We demonstrated a
hyperfibrinolytic state in hemophilia,11,12 factor XI deficiency,13
and after use of heparin and heparin-like anticoagulants14,15 as a
consequence of reduced thrombin generation resulting in defective
TAFI activation. In patients with liver disease, plasma fibrinolytic
potential was similar to that in controls, despite severely reduced
TAFI levels, which could be explained by a concomitant decrease
in profibrinolytic proteins.10 During oral contraceptive use, overall
plasma fibrinolytic potential did not change, but factor XI–
independent CLTs were prolonged.16
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Here, we assessed the contribution of the fibrinolytic system to
the development of venous thrombosis. For this, our CLT assay,
which measures global plasma fibrinolytic potential, taking the
interplay between coagulation and fibrinolysis (eg, through TAFI)
into account, was used. This study was part of the Leiden
Thrombophilia Study (LETS), a large population-based case-
control study designed to estimate the contributions of genetic and
acquired factors to the risk of venous thrombosis.
Patients, materials, and methods
Patients
The design of the LETS has been extensively described previously.17,18 In
short, 474 consecutive patients with an objectively confirmed first episode
of DVT that occurred between January 1988 and December 1992 were
selected from 3 anticoagulation clinics in The Netherlands. Patients were
younger than 70 years and had no known malignancy. Controls were
acquaintances or partners, and they were matched for age and sex.
Blood was collected in tubes containing 0.106 M trisodium citrate.
Plasma was prepared by centrifugation at 2000g for 10 minutes at room
temperature and stored at 70°C. Samples were obtained at least 6 months
after the thrombotic event and at least 3 months after discontinuation of oral
anticoagulant treatment. For this study, plasma samples from 469 controls
and 469 patients were available. However, 48 patients were excluded from
the analysis because they were still using oral anticoagulation at the time of
venipuncture. Samples, which were kept at70°C at all times and were not
previously thawed, were used for this study. Approval for this study was
obtained from the Institutional Review Board of the Leiden University
Medical Center. Informed consent was provided according to the Declara-
tion of Helsinki.
Clot lysis assay
Lysis of a tissue factor–induced clot by exogenous tPA was studied by
monitoring changes in turbidity during clot formation and subsequent lysis
essentially as described previously, except for a change in tissue factor
concentration.10 Plasma (50 L) was pipetted into a microtiter plate, after
which 50 L of a mixture containing tissue factor (diluted Innovin; Dade
Behring, Marburg, Germany; final dilution 1000 times), CaCl2 (final
concentration 17 mM), tPA (Chromogenix, Mo¨lndal, Sweden; final concen-
tration 30 U/mL; 56 ng/mL), and phospholipid vesicles (consisting of 40%
L--dioleoylphosphatidylcholine, 20% L--dioleoylphosphatidylserine, and
40% L--dioleoylphosphatidylethanolamine, all from Sigma, St Louis,
MO, prepared according to Brunner et al19 with minor modifications as
described by van Wijnen et al20; final concentration 10 M), diluted in
HEPES buffer (25 mM HEPES [N-2-hydroxytethylpiperazine-N-2-
ethanesulfonic acid], 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2, 0.1%
bovine serum albumin [BSA], pH 7.4) was added. After thorough mixing,
turbidity at 405 nm was measured in time at 37°C in a Spectramax 340
kinetic microplate reader (Molecular Devices Corporation, Menlo Park,
CA). CLT was defined as the time from the midpoint of the clear to
maximum turbid transition, which characterizes clot formation, to the
midpoint of the maximum turbid to clear transition, which represents clot
lysis. The intra-assay and interassay coefficients of variation were 3.4%
(n  16) and 4.0% (n  32), respectively. All assays were performed
without knowledge of whether the sample was from a patient or a control.
Statistical analysis
Data were analyzed with 2 objectives. First, determinants of CLT were
assessed in the control subjects as reflecting the general population.
Determinants were established by comparing means and using linear
regression. Second, it was investigated whether elevated CLT is a risk factor
for DVT by calculating odds ratios (ORs) and 95% confidence intervals
(CIs). As cut-off points we used percentiles (70, 80, 90, 95, and 99) of CLTs
measured in the control subjects. We used multivariate modeling by
unconditional logistic regression to adjust for sex, age, and other putative
confounding variables.
Results
In this study, 421 patients and 469 controls were used. The mean
age of the patients and controls was 45 years (range, 14-69 years in
patients; 14-72 years in controls). In the control population 47%
were male, whereas 43% of the patients were male.
Determinants of CLTs
Determinants of CLTs in the control population are shown in Table
1. The mean of the CLTs in the 469 control subjects was 61.0
minutes (range, 38.8-135.2 minutes). CLTs were slightly higher in
men than in women (mean difference, 3.3 minutes; 95% CI,
1.3-5.3). CLTs progressively increased with age and were reduced
by oral contraceptive use, although this effect was small.
To investigate the relationship between levels of clotting factors
and the CLT, univariate regression analysis was performed. Table 2
shows regression coefficients (b) and their 95% CIs for all the
tested variables. Although the levels of several coagulation factors
were associated with the CLTs, all associations were weak,
indicating that levels of these factors only to a small extent
determined the CLT in our assay. A weak association between CLT
and the endogenous thrombin potential was present; however, this
association disappeared after correction for age, indicating that
CLTs were not influenced by the thrombin-generating capacity of
the plasma. No association between CLT and TFPI activity, total
TFPI, factor XIII activity, and factor XIII a-subunit could be
demonstrated.
CLT as a risk factor for DVT
For determination of the contribution of elevated CLTs to the risk
of DVT, cut-off levels of CLTs in the control group were set at the
70th, 80th, 90th, 95th, and 99th percentiles. The ORs for DVT in
subjects with CLTs above these cut-off values, with values below
the cut-off as reference group, progressively increased over the
range of cut-off levels (Table 3). For a cut-off point at the 90th
percentile, 18% of the individuals with DVT had a CLT above this
cut-off, compared to 10% (per definition) in the control group. This
implies that CLTs above 74.1 minutes were associated with an
almost 2-fold increased risk of DVT (OR, 1.9; 95% CI, 1.3-2.9).
After adjustment for sex and age, the OR for the 90th percentile
was 2.0 (95% CI, 1.3-3.0). After adjustment for all factors that,
Table 1. CLTs in control subjects
No. of
subjects
CLT,
mean min
Sex
Male 198 63.0
Female 271 59.7
Use of oral contraceptives in premenopausal women
Yes 67 53.4
No 114 56.9
Age, y
24 or younger 42 53.9
25-34 55 54.2
35-44 104 59.1
44-54 133 62.7
55 and older 135 66.0
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after correction for age, had shown an association with CLTs in the
controls (levels of fibrinogen, factors II, VII, X, V, XI, TAFI factor
XIII b subunit, TFPI [free], and antithrombin III), the risk remained
elevated at an OR of 1.6 (95% CI, 1.0-2.5).
Discussion
This study shows that individuals with reduced fibrinolytic poten-
tial, as measured by a plasma-based assay, have an increased risk of
developing a first venous thrombosis. The risk of thrombosis
increased with increasing plasma CLT. Individuals with a plasma
CLT above the 90th percentile of the control subjects have an
almost 2-fold increased risk for development of a first DVT. The
risk remained elevated even after extensive adjustment for other
factors, and therefore is likely to be indicative of a real effect. The
relative risk of 1.9 associated with elevated CLTs, which are
present in 10% of the population, suggests that plasma hypofibrin-
olysis is an important contributor to the overall burden of venous
thrombosis. Based on these data, the population-attributable risk of
thrombosis is 9% (ie, 9% of all cases of thrombosis in the general
population may be attributable to plasma hypofibrinolysis). The
relative risk of 1.9 at the 90th percentile of CLTs in control subjects
indicates that plasma hypofibrinolysis forms a risk for venous
thrombosis comparable to the risk associated with other risk factors
such as high levels of factor XI21 (relative risk, 2.2 at levels above
the 90th percentile of the controls), high levels of factor IX22
(relative risk, 2.3 at levels above the 90th percentile of the
controls), and heterozygotes for the prothrombin G20210A muta-
tion (relative risk, 2.8).23
In this study we show for the first time a clear association
between plasma hypofibrinolysis and the risk of thrombosis. The
role of the fibrinolytic system in DVT has been debated.24 Previous
studies have either examined single fibrinolytic parameters (tPA
and PAI-1 activity or antigen, PAI-1 4G/5G polymorphism),
plasma markers of fibrinolysis (PAP complexes, tPA/PAI-1 com-
plexes), or clot lysis assays in which fibrinolytic potential was only
assessed partially, that is, in a plasma fraction, or in the absence of
calcium (ELT or DWBCLT, respectively), and were often in small
or selected groups of patients.4-6,8,9 Here, we have used a tissue
factor–induced clotting assay, in which fibrinolysis is initiated by
exogenous tPA in a large population-based case-control study. The
outcome of the assay presumably represents an overall measure for
the plasma fibrinolytic potential resulting from a combination of
plasma levels of proteins important for clot dissolution. Indeed, we
have shown previously that this clot lysis assay is influenced by
levels of plasminogen, 2-antiplasmin, PAI-1, and TAFI.10 In
accordance, in this study, in which individuals have been character-
ized very extensively, no strong associations of proteins involved in
clot formation were observed.
Surprisingly, TAFI levels were only weakly associated with
CLTs. Previously, it has been demonstrated that addition of purified
TAFI to TAFI-depleted plasma dose-dependently prolongs CLT.25
Moreover, an association between TAFI antigen levels and CLTs
were found in plasma samples from 20 healthy volunteers.25 In this
study we show that although an association between TAFI antigen
levels and CLTs exists, the contribution of TAFI levels to CLTs is
small. In other words, the CLT in a given plasma sample is
determined by the total fibrinolytic capacity of the plasma, which is
determined by the balance of the levels of all fibrinolytic proteins.
No association between the thrombin-generating capacity of the
plasma (endogenous thrombin potential [ETP]) and CLT could be
demonstrated, which is in contrast with earlier observations in
which the extent of TAFI activation was linked to the amount of
thrombin generated after clot formation via the factor XI feedback
loop.13 Also, both in the present study and in literature,26 CLTs were
associated with prothrombin plasma levels, which were shown to
be accompanied by an increased generation of activated TAFI.
Because it was previously demonstrated that ETP values are
strongly linked to prothrombin plasma levels,27 it is surprising that
no association between ETP and CLTs times was found now.
The risk for DVT associated with plasma hypofibrinolysis did
not disappear after adjustment for all variables shown to influence
CLTs in the control population. This again is an indication that the
risk of DVT associated with prolonged CLTs reflects abnormalities
in the fibrinolytic system. Unfortunately, levels of fibrinolytic
proteins, such as plasminogen, 2-antiplasmin, and PAI-1, as well
as the PAI-1 4G/5G polymorphism, have not been measured in the
LETS population. Consequently, potential denominators of the
CLT in terms of proteins known to be important in fibrinolysis
could not be elucidated from this study.
Our clot lysis assay is presumably not sensitive for variations in
plasma levels of tPA or urokinase, because a fixed amount of
exogenous tPA is added in the assay to induce clot lysis. Also, a
contributory role of factor XIII in determining CLTs was excluded
from the present study. No association between CLT and factor XIII
activity or the a-subunit antigen level could be demonstrated. An
association between the catalytically inactive factor XIII b-subunit
and CLT was present, which may indicate that the b-subunit has an
Table 2. Association of CLTs with levels of coagulation factors and
the ETP
b (95% CI)
b (95% CI) adjusted
for age
Fibrinogen, g/L 3.251 (1.758-4.744) 1.963 (0.540-3.387)
Factor II, % 0.160 (0.092-0.227) 0.163 (0.102-0.225)
Factor VII, % 0.121 (0.076-0.166) 0.090 (0.050-0.135)
Factor VIII, % 0.004 (0.026-0.034) 0.016 (0.044-0.013)
Factor IX, % 0.058 (0.049-0.111) 0.033 (0.017-0.083)
Factor X, % 0.064 (0.001-0.129) 0.105 (0.044-0.166)
Factor V, % 0.070 (0.041-0.100) 0.038 (0.010-0.068)
Factor XI, % 0.091 (0.041-0.141) 0.074 (0.028-0.122)
TAFI, % 0.228 (0.149-0.306) 0.188 (0.115-0.261)
Factor XIII, b-subunit, % 0.182 (0.109-0.255) 0.145 (0.074-0.214)
Free TFPI, ng/mL 0.953 (0.715-1.192) 0.762 (0.519-1.004)
Antithrombin III, % 0.050 (0.047-0.146) 0.107 (0.017-0.196)
C-reactive protein, g/mL 0.095 (0.107-0.297) 0.076 (0.110-0.263)
ETP, nM IIa  min 0.001 (0.002-0.000) 0.000 (0.001-0.000)
The regression coefficient b shows the increase in clot lysis time (in minutes) per
unit increase in the variable studied. Also shown are regression coefficients after
correction for age. Levels of coagulation factors are expressed as percentage of
pooled normal plasma (ie, U/dL), except for TFPI and fibrinogen and other variables
as indicated.
Table 3. Risk of venous thrombosis according to CLTs
Cut-off, percentile
Lysis time at
cut-off, min
No. of
patients
No. of
controls
OR (95%
CI)
70 65.4 158 141 1.4 (1.1-1.8)
80 68.6 119 94 1.6 (1.2-2.1)
90 74.1 75 47 1.9 (1.3-2.9)
95 79.3 42 23 2.1 (1.3-3.6)
99 97.8 8 4 2.2 (0.7-7.5)
Cut-off levels of CLTs in the control group were set at the 70th, 80th, 90th, 95th,
and 99th percentiles, and ORs for the development of DVT were calculated.
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until now incompletely understood role in modulation of fibrinoly-
sis. Thus, the outcome of our assay represents a tPA- and factor
XIII-independent measure of the plasma fibrinolytic potential.
Our findings that hypofibrinolysis plays a role in the develop-
ment of a first venous thrombosis is supported by a recent
publication in which an asymptomatic venous thrombus was
detected in 1% of a healthy population (n  1213).28 The fact that
small, nonsymptomatic thrombi occur this frequently may explain
why a defective fibrinolytic system, that is, the incapacity to
remove these asymptomatic thrombi, is associated with a higher
risk for thrombosis.
In conclusion, hypofibrinolysis, as measured by a tissue factor–
and tPA-induced plasma-based clot lysis assay is a risk factor for
the development of a first DVT. Whether this hypofibrinolytic state
is determined by genetic or acquired factors, or a combination of
these, and which proteins are involved is at present unknown.
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